1. Introduction
Over the last 3 years, the nightmarish COVID-19 pandemic imposed unprecedented non-pharmaceutical interventions (NPIs) which impacted the epidemiology of many other pediatric infectious diseases [1], [2]. Prolonged reduction of exposure to many viruses and bacteria resulted in a lack of immune stimulation against varied community-acquired pathogens, leading to expansion of the “naive” population to these pathogens and to the decline of herd immunity, making children more vulnerable to these infections [3]. In this context and in this journal, a year and a half ago our group put forward the concept of “immune debt”[3]. Briefly, after barrier measures were lifted, we raised concerns about the epidemiological rebound of many infectious diseases of varying severity and the occurrence of unpredictable epidemics throughout one year [3], [4]. Worldwide, many researchers published articles concurring with our concept of “immunity debt”, which is also called “immunity gap” [5], [6], [7], [8]. Unfortunately, due to possible misunderstanding and oversimplification of our concept, many controversies and polemics arose on social media and networks, and a backlash ensued.
The aim of this article is to highlight aspects of the concept that were not sufficiently understood by its detractors, to provide clarifications, and to deliver a brief overview of our innovative hypothesis.
2. Major clarifications
-
-
We fully agree that the NPIs in place to contain the COVID-19 pandemic were necessary, but are also convinced that like any therapeutic measure, they may have had unexpected consequences [9].
-
-
We never affirmed that NPIs would weaken the immune capacities of individuals or that lack of exposure to pathogens such as respiratory syncytial virus (RSV) and influenza could irrevocably damage the immune system. We simply suggested that due to a lack of pathogen exposure, NPIs could decrease some children’s adaptative immunity to specific pathogens.
-
-
From our standpoint $, immune debt should also be considered at the population level. If this winter, numerous infants in many countries are hospitalized for bronchiolitis, it is partly because the whole population, including adults, especially parents of very young infants, have become more susceptible to respiratory viruses (mainly RSV, viruses known for their limited and transient immunity despite iterative reinfections) leading to their increased circulation and transmission in the community. Furthermore, some mothers may have transmitted lower levels of RSV antibodies to their newborns, thereby reducing their protection [10].
3. Facts supporting our hypotheses
In France and in many other countries, the “immunity debt” has come due and is being to have been paid with interest [5], [6], [11], [12], [13], [14], [15]. Today, we are facing an unprecedented bronchiolitis outbreak in France with a higher and earlier (6-week) peak [16]. The intensity and the precocity of the epidemic lend credence to the immunity debt concept. The new epidemic pattern, which has entailed overload of hospital emergency services, wards and intensive care units, should have been anticipated by health authorities -- and requires urgent and specific appropriate responses [4], [17]. The NPIs targeting very young children should be quickly implemented for their protection and so as to counteract the consequences of the immune debt.
We recently summarized the relevant trends in a French community-acquired infection networks in a prospective multicentric surveillance study (PARI, Pediatric and Ambulatory Research in Infectious diseases) [14]. We showed that after having fallen in 2020, in 2021 the number of consultations for infectious diseases increased to a level never reached before [14]. Pediatric diseases such as enterovirus infections raise specific concerns, and we observed an unprecedentedly high peak in France in July 2021 [18], [19]. Similar findings were reported for otitis media and gastroenteritis. Once again, the intensity of these outbreaks underscores the relevance of the immunity debt concept [14].
Lastly, the increased number of antibiotic prescriptions in many European countries as well as the USA, Canada and Australia might be another indirect consequence of the “immunity debt” [20], [21], [22], [23]. Unfortunately, the increase was reported without any change in guidelines for pediatric antibiotic use and resulted in antibiotic shortages, particularly for amoxicillin [20], [21], [22], [24].
In England, where meningococcal B vaccination recommendation is limited to infants, an unusually sharp increase in invasive serogroup B meningococcal infections was reported in adolescents who had only been vaccinated against ACYW serotypes [24]. The number of cases exceeded the pre-pandemic number. The serogroup and age distribution suggested that ACWY meningococcal vaccination programmes in adolescents maintained low rates of group C, W, and Y disease due to herd immunity. By contrast, low immunity against group B strains in adolescents and young adults and high level of carriage and transmission of these strains resulted in the resurgence of invasive group B disease [24]. COVID-19 pandemic lockdowns reduced the opportunities for meningococcal exposure among adolescents and decreased carriage, which may have resulted in another ‘immunity debt’ in this population [24]. In the coming weeks or months, an increase in invasive bacterial infections is to be feared not only for invasive meningococcal diseases, but also for pneumococcal and even group A streptococcal (GAS) infections, which are also partially due to the resurgence of viral diseases in children [25]. In point of fact, the latest data from the UK Health Security Agency show a higher number of GAS infections, albeit without evidence that a new strain is circulating. The investigations presently underway have shown that the increase is most likely related to high amounts of circulating bacteria and social mixing [26]. Similarly in France, several invasive GAS infections have been reported in children under 10 years of age [27].
4. Conclusion
These findings buttress the general concept of “immunity debt”, which may be manifested at various levels, according to different pathogens and their ways iof transmission. Each country needs to strengthen its immunization program so as to limit the consequences of the immune debt and to improve infectious disease surveillance, the objective being to better anticipate future epidemics.
Authors’ contributions
RC and CL wrote the manuscript. All other authors revised and approved the manuscript.
Availability of data
No data.
Conflicts of interests
CL received personal fees and non-financial support from Pfizer and MSD outside the submitted work.
AR received non-financial support from Pfizer, and AstraZeneca, outside the submitted work.
FA received personal fees and non-financial support from Pfizer, GSK, MSD, and Sanofi, outside the submitted work.
NO declares no competing interests for this study.
EG declares no competing interests for this study.
References
- 1.Belingheri M., Paladino M.E., Piacenti S., Riva M.A. Effects of COVID-19 lockdown on epidemic diseases of childhood. J Med Virol. 2021;93(1):153–154. doi: 10.1002/jmv.26253. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Brueggemann A.B., Jansen van Rensburg M.J., Shaw D., McCarthy N.D., Jolley K.A., Maiden M.C.J., et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. Lancet Digit. Health. 2021;3(6):e360–e370. doi: 10.1016/S2589-7500(21)00077-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Cohen R., Ashman M., Taha M.K., Varon E., Angoulvant F., Levy C., et al. Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap? Infect Dis Now. 2021;51(5):418–423. doi: 10.1016/j.idnow.2021.05.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Cohen R., Pettoello-Mantovani M., Somekh E., Levy C. European Pediatric Societies Call for an Implementation of Regular Vaccination Programs to Contrast the Immunity Debt Associated to Coronavirus Disease-2019 Pandemic in Children. J Pediatr. 2022;242(260–1):e3. doi: 10.1016/j.jpeds.2021.11.061. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Hatter L., Eathorne A., Hills T., Bruce P., Beasley R. Respiratory syncytial virus: paying the immunity debt with interest. Lancet Child Adolesc Health. 2021;5(12):e44–e45. doi: 10.1016/S2352-4642(21)00333-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Willyard C. Flu and colds are back with a vengeance — why now? https://wwwnaturecom/articles/d41586-022-03666-9. (accessed 08 Dec 2022). [DOI] [PubMed]
- 7.Messacar K., Baker R.E., Park S.W., Nguyen-Tran H., Cataldi J.R., Grenfell B. Preparing for uncertainty: endemic paediatric viral illnesses after COVID-19 pandemic disruption. Lancet. 2022;400(10364):1663–1665. doi: 10.1016/S0140-6736(22)01277-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Christensen J. Pandemic « immunity gap » is probably behond surge in RSV cases, scientists say https://editioncnncom/2022/10/26/health/rsv-immunity-gap/indexhtml. (accessed 08 Dec 2022).
- 9.Flaxman S., Mishra S., Gandy A., Unwin H.J.T., Mellan T.A., Coupland H., et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature. 2020;584(7820):257–261. doi: 10.1038/s41586-020-2405-7. [DOI] [PubMed] [Google Scholar]
- 10.Buchwald A.G., Graham B.S., Traore A., Haidara F.C., Chen M., Morabito K., et al. Respiratory Syncytial Virus (RSV) Neutralizing Antibodies at Birth Predict Protection from RSV Illness in Infants in the First 3 Months of Life. Clin Infect Dis. 2021;73(11):e4421–e4427. doi: 10.1093/cid/ciaa648. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Rybak A., Levy C., Jung C., Bechet S., Batard C., Hassid F., et al. Delayed Bronchiolitis Epidemic in French Primary Care Setting Driven by Respiratory Syncytial Virus: Preliminary Data from the Oursyn Study, March 2021. Pediatr Infect Dis J. 2021 doi: 10.1097/INF.0000000000003270. [DOI] [PubMed] [Google Scholar]
- 12.Taylor A., Whittaker E. The Changing Epidemiology of Respiratory Viruses in Children During the COVID-19 Pandemic: A Canary in a COVID Time. Pediatr Infect Dis J. 2022;41(2):e46–e48. doi: 10.1097/INF.0000000000003396. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Baker R.E., Park S.W., Yang W., Vecchi G.A., Metcalf C.J.E., Grenfell B.T. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. Proc Natl Acad Sci U S A. 2020;117(48):30547–30553. doi: 10.1073/pnas.2013182117. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Cohen P.R., Rybak A., Werner A., Bechet S., Desandes R., Hassid F., et al. Trends in pediatric ambulatory community acquired infections before and during COVID-19 pandemic: A prospective multicentric surveillance study in France. Lancet Reg Health Eur. 2022;22 doi: 10.1016/j.lanepe.2022.100497. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Foley D.A., Yeoh D.K., Minney-Smith C.A., Martin A.C., Mace A.O., Sikazwe C.T., et al. The Interseasonal Resurgence of Respiratory Syncytial Virus in Australian Children Following the Reduction of Coronavirus Disease 2019-Related Public Health Measures. Clin Infect Dis. 2021 doi: 10.1093/cid/ciaa1906. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Pediatric Infectious disease surveillance, PARI network. https://wwwinfovacfr/actualites/donnees-du-reseau-pari-semaine-du-14-novembre-2022. (accessed 08 Dec 2022).
- 17.Cohen R., Gillet Y., Le Guen C.G., Weil-Olivier C., Hau I., Dufour V., et al. Vaccination, or how to alleviate the crisis in pediatric emergency units. Infect Dis Now. 2022;52(7):386–388. doi: 10.1016/j.idnow.2022.09.001. [DOI] [PubMed] [Google Scholar]
- 18.https://www.infovac.fr/reseau-pari?layout=list&types[0]=1. (accessed 08 Dec 2022).
- 19.Mirand A., Cohen R., Bisseux M., Tomba S., Sellem F.C., Gelbert N., et al. A large-scale outbreak of hand, foot and mouth disease, France, as at 28 September 2021. Euro Surveill. 2021;26(43) doi: 10.2807/1560-7917.ES.2021.26.43.2100978. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.FDA Drug Shortages. https://wwwaccessdatafdagov/scripts/drugshortages/dsp_ActiveIngredientDetailscfm?AI=Amoxicillin%20Oral%20Powder%20for%20Suspension&st=c. (accessed 08 Dec 2022).
- 21.Shortage of 'first-line' antibiotic hits as surge in children's respiratory illnesses strains supply. https://wwwcbcca/news/canada/toronto/amoxicillin-shortage-children-respiratory-llness-16641392. (accessed 08 Dec 2022).
- 22.Soni A, Herbert C, Filippaios A, Broach J, Colubri A, Fahey N, et al. Comparison of Rapid Antigen Tests′ Performance between Delta (B.1.61.7; AY.X) and Omicron (B.1.1.529; BA1) Variants of SARS-CoV-2: Secondary Analysis from a Serial Home Self-Testing Study. medRxiv. 2022:2022.02.27.22271090. [DOI] [PMC free article] [PubMed]
- 23.Amoxicillin Shortage: Antibiotic Options for Common Pediatric Conditions. https://publicationsaaporg/redbook/resources/22761?autologincheck=redirected?nfToken=00000000-0000-0000-0000-000000000000. (accessed 08 Dec 2022).
- 24.Clark S.A., H. C, Mensah A.A., Lekshmi A., Walker A., Ribeiro S., et al. An increase in group B invasive meningococcal disease among adolescents and young adults in England following easing of COVID-19 containment measures. https://papersssrncom/sol3/paperscfm?abstract_id=3998164. (accessed 08 Dec 2022).
- 25.Danino D., Ben-Shimol S., van der Beek B.A., Givon-Lavi N., Avni Y.S., Greenberg D., et al. Decline in Pneumococcal Disease in Young Children During the Coronavirus Disease 2019 (COVID-19) Pandemic in Israel Associated With Suppression of Seasonal Respiratory Viruses, Despite Persistent Pneumococcal Carriage: A Prospective Cohort Study. Clin Infect Dis. 2022;75(1):e1154–e1164. doi: 10.1093/cid/ciab1014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.UKHSA update on scarlet fever and invasive Group A strep. https://wwwgovuk/government/news/ukhsa-update-on-scarlet-fever-and-invasive-group-a-strep. (accessed 08 Dec 2022).
- 27.Invasive Group A Streptococcal Disease, December 6, 2022. https://wwwsantepubliquefrancefr/les-actualites/2022/infection-invasive-a-streptocoque-du-groupe-a-iisga-point-de-situation-au-6-decembre-2022. (accessed 08 Dec 2022).
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
No data.